J. Goldman & Co’s Apellis Pharmaceuticals APLS Stock Holding History

J. Goldman & Co’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-89,600	Closed	-$2.25M	–	662
2025 Q4	$2.25M	Buy	89,600 +39,500	+79%	+$927K	0.06%	300
2025 Q3	$1.13M	Buy	+50,100	New	+$1.17M	0.03%	324
2023 Q3	–	Sell	-13,500	Closed	-$1.23M	–	364
2023 Q2	$1.23M	Buy	+13,500	New	+$1.16M	0.04%	240
2022 Q4	–	Sell	-54,000	Closed	-$3.69M	–	371
2022 Q3	$3.69M	Buy	+54,000	New	+$3.2M	0.18%	147
2021 Q2	–	Sell	-13,500	Closed	-$579K	–	404
2021 Q1	$579K	Buy	+13,500	New	+$639K	0.02%	346

Other funds holding APLS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

J. Goldman & Co's APLS Position: Q1 2026 in Review

J. Goldman & Co sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 285,992 shares — an estimated $7.18M sold.

J. Goldman & Co first reported a position in APLS in Q4 2021 and held it in 7 quarters. The position peaked at $7.18M in Q4 2025. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

J. Goldman & Co reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
J. Goldman & Co sold 285,992 Apellis Pharmaceuticals shares in Q1 2026, an estimated $7.18M.
J. Goldman & Co first reported a position in Apellis Pharmaceuticals in Q4 2021 and held it in 7 quarters.
J. Goldman & Co's Apellis Pharmaceuticals position peaked at $7.18M in Q4 2025.
321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.